PALB2 and prostate carcinoma: We tested the impact of PALB2 or BARD1 loss on olaparib and rucaparib sensitivity across prostate cancer cell lines and observed a significant increase in sensitivity in PALB2- or BARD1-depleted cells compared to control cells across the cell line models (Fig. 3; Supplementary Figs. 5–8).